Xi C Chen

20060100225, May 11, 2006

Mar 23, 2005

11/088276

Xi Chen - Killingworth CT, US
Andrew Thurkauf - Ridgefield CT, US
Shirley Louise-May - Guilford CT, US

A61K 31/513
A61K 31/505
C07D 239/32

514269000, 514275000, 544320000, 544330000

Compounds of Formula 1, and pharmaceutically acceptable forms thereof, are provided: wherein the variables X, Y, Z, A, R, R, R, Rand Rare defined herein. Certain compounds of Formula 1 described herein which possess potent antiviral activity. Certain compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. Pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are also provided. Methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease or disorder are disclosed. These infectious diseases include viral infections, particularly HCV infections. Methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.

60342528, Mar 7, 2000

Jun 8, 1999

9/328170

Xi Chen - Killingworth CT
Jan W. F. Wasley - Guilford CT

Neurogen Corporation - Branford CT

C07D49504

5483595

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable salts thereof wherein wherein: R. sub. 1, R. sub. 2, and and R. sub. 4 independenlty represent hydrogen, halogen, alkyl, cyano, alkoxycarbonyl, trifluoromethoxy, SO. sub. 2 NH. sub. 2 or trifluoromethyl; R. sub. 3 represents hydrogen, halogen, alkyl, alkoxy, alkylthio, hydroxy, amino, mono- or di(C. sub. 1 -C. sub. 6)alkylamino, cyano, alkoxycarbonyl, trifluoromethoxy, SO. sub. 2 NH. sub. 2 or trifluoromethyl; or R. sub. 3 represents optionally substituted phenyl; X represents (CH. sub. 2). sub. n where n is an integer; and m is 0 or an integer, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

62914634, Sep 18, 2001

Jun 30, 1999

9/345034

Xi Chen - Killingworth CT

Neurogen Corporation - Branford CT

A61K 31496
C07D41704

51425402

Disclosed are compounds of the formula: ##STR1## or pharmaceutically acceptable addition salts thereof wherein: R. sub. 1 and R. sub. 2 are the same or different and represent hydrogen, halogen, C. sub. 1 -C. sub. 6 alkyl, C. sub. 1 -C. sub. 6 alkoxy, C. sub. 1 -C. sub. 6 alkylthio, hydroxy, amino, mono- or di(C. sub. 1 -C. sub. 6)alkylamino, cyano or trifluoromethyl; Ar represents aryl or heteroaryl, each of which is optionally substituted with R. sub. 3, R. sub. 4 and/or R. sub. 4 ; R. sub. 3, R. sub. 4, and R. sub. 6 independently represent hydrogen, halogen, hydroxy, C. sub. 1 -C. sub. 6 alkyl, C. sub. 1 -C. sub. 6 alkoxy, perfluoro(C. sub. 1 -C. sub. 6)alkyl, perfluoro(C. sub. 1 -C. sub. 6)alkoxy, or SO. sub. 2 NH. sub. 2 ; or R. sub. 3 and R. sub.

62882309, Sep 11, 2001

Sep 29, 1999

9/408035

Xi Chen - Killingworth CT

Neurogen Corporation - Branford CT

C07D24102
C07D40500
C07D40300
C07D23354
C07D31708

544295

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof wherein: n is an integer; R. sub. 1 represents an organic or inorganic group; R. sub. 2 represents halogen or C. sub. 1 -C. sub. 6 alkyl; R. sub. N is an alkylene carrying a substituted piperazine, piperidine, or tetrahydropyridine; and R. sub. 4 is hydrogen or C. sub. 1 -C. sub. 6 alkyl, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

20220370633, Nov 24, 2022

Jun 8, 2022

17/835026

- Cambridge MA, US
Xi Chen - West Newton MA, US

Ultivue, Inc. - Cambridge MA

A61K 47/68
G01N 33/58
C07K 16/12
G01N 33/68
C07K 16/42
G01N 33/536

A method for exchange imaging of at least two targets in a sample includes (a) incubating a sample with at least two or more target-recognizing antibodies, each bound to a corresponding monovalent tight antibody binder-docketing moiety (MTAB-DM) reagent capable of binding monovalently to the target-recognizing antibodies, (b) applying at least two imager moieties corresponding to the MTAB-DM, either in series, in batches, or in parallel, and (d) imaging the at least two imager moieties either in series, in batches, or in parallel.

20230027974, Jan 26, 2023

Jul 8, 2022

17/811486

- Cambridge MA, US
Sarit Agasti - Cambridge MA, US
Xi Chen - Cambridge MA, US
Ralf Jungmann - Cambridge MA, US

President and Fellows of Harvard College - Cambridge MA

C12Q 1/6804
C12Q 1/6818

The present invention provides, inter alia, methods and compositions for imaging, at high spatial resolution, targets of interest.

20210396760, Dec 23, 2021

Jun 30, 2021

17/363416

- Cambridge MA, US
Xi Chen - West Newton MA, US

Ultivue, Inc. - Cambridge MA

G01N 33/58
G01N 21/64
C07K 16/18
G01N 33/533

An imaging agent comprises (a) at least one target recognition moiety; (b) at least one observable moiety non-transiently bound to the target recognition moiety, and (c) at least one docking moiety bound to the target recognition moiety, wherein the docking moiety is capable of transiently binding at least one observable moiety. In some embodiments, the at least one target recognition moiety is an antibody or antigen binding fragment thereof.

20210032677, Feb 4, 2021

Aug 9, 2018

16/637456

- Boston MA, US
Xi Chen - Newton MA, US

RootPath Genomics, Inc. - Boston MA

C12Q 1/6806
C12Q 1/6869
C12N 15/10

The application provides improved methods of analyzing biological particles and their constituents, including methods of generating truncated and barcoded nucleic acid molecules from at least two target polynucleotide sequences, each from distinct biological particles.